According to UTSW, killing the bad cells without also getting rid of the healthy ones during cancer treatment may be possible after researchers zero in on a protein called midnolin.
In this image, provided by UTSW, the proteasome—a cell’s protein disposal system—is shown in tan and grey. A protein called midnolin is shown in red. It plays a critical role in helping malignant B cells stay alive in cancers like leukemia, lymphoma, and multiple myeloma. By figuring out its structure using cryo-electron microscopy, UTSW researchers say they’ve opened the door to new therapies that could target midnolin—and potentially shut it down—without harming healthy cells.
The work could lead to new pharmaceuticals that avoid the serious side effects of current therapies. For the full story, go to Dallas Innovates.
